- Birth length below -2 SD
- Height at start below - 2 Sd
- Any endocrine or chronic disease
- Any known syndrome with short stature
The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)
- Birth length below -2 SD
- Height at start below - 2 Sd
- Any endocrine or chronic disease
- Any known syndrome with short stature
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021